16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      1423. Plasma and Intrapulmonary Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients With Pneumonia

      abstract

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Pneumonia is a major cause of mortality in critically ill patients. Sitafloxacin, broad-spectrum fluoroquuinolone, has an in vitro activity against many drug-resistant pathogens causing pneumonia. The objectives of this study were to determine epithelial lining fluid (ELF) concentrations of sitafloxacin and compare those with plasma, including pharmacokinetic (PK) parameters in Thai critically ill patients.

          Methods

          Sitafloxacin concentrations were determined using LC–MS/MS assay. Twelve critically ill patients with pneumonia were enrolled to receive oral sitafloxacin 200 mg single dose. Serial blood samples were collected in each patient (seven time points) prior to dose and over 12-hour interval. BAL samples were collected once in each patient simultaneously with plasma sampling. Intrapulmonary penetration was evaluated as the ELF to unbound plasma concentration ratio calculated by fraction unbound related to albumin concentration in each patient. A compartment model was applied to describe plasma PK parameters using WinNonLin software.

          Results

          The median age was 57 years with median weight was 52 kg. The highest penetration ratio of ELF to unbound plasma concentrations based on median value was 1.3, observed during 5–6 hours (Table 1). The data fitted to one-compartment model that described absorption, distribution and elimination. PK parameters are presented in Table 2.

          Conclusion

          Oral sitafloxacin well penetrate into ELF at a penetration ratio of 130% related to unbound plasma in Thai critically ill patients. Sitafloxacin is a promising agent for treatment of lower respiratory tract infections caused by susceptible pathogens in intensive care unit.

          Table 1:

          Penetration Ratio Based on Median of Sitafloxacin Concentrations in Each Sampling Time

          BAL Fluid Sampling Time (hour) Sample ( n) ELF Conc. (µg/mL) Unbound Plasma Conc. (µg/mL) Ratio ELF: Unbound Plasma Penetration (%)
          0.5 - 2 3 0.09 0.29 0.3 30
          3 - 4 3 0.50 0.91 0.5 50
          5–6 3 0.84 0.64 1.3 130
          7–9 3 0.22 0.42 0.5 50
          Table 2:

          PK parameters of sitafloxacin 200 mg single dose based on the median values (min–max).

          PK Parameters Plasma ELF
          T max (h) 3.7 (1–8) 5.5
          C max (µg/mL) 1.5 (0.48–1.82) 0.84
          K a (h −1) 10.84 (3.64–48.49) NA
          CL/ F (mL/minute) 221.62 (45.13–533.22) NA
          V/ F (L) 148.92 (100.88–361.81) NA
          AUC 0–12 (µg ·hour/mL) 10.84 (3.64–48.49) NA

          K a, absorption rate constant; NA, not applicable.

          Disclosures

          T. Paiboonvong, Daiichi Sankyo (Thailand) LTD.: Grant support, Research support. V. Tangsujaritvijit, Ramathibodi Hospital: Grant support, Research support.

          Related collections

          Author and article information

          Journal
          Open Forum Infect Dis
          Open Forum Infect Dis
          ofid
          Open Forum Infectious Diseases
          Oxford University Press (US )
          2328-8957
          November 2018
          26 November 2018
          26 November 2018
          : 5
          : Suppl 1 , ID Week 2018 Abstracts
          : S439
          Affiliations
          [1 ]Faculty of Pharmacy, Siam University, Bangkok, Thailand
          [2 ]Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
          [3 ]Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
          Article
          ofy210.1254
          10.1093/ofid/ofy210.1254
          6254081
          31417985-fa46-40de-8a2b-4cb4762d674c
          © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

          This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

          History
          Page count
          Pages: 1
          Categories
          Abstracts
          Poster Abstracts

          Comments

          Comment on this article